You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Details for Patent: 7,888,342


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,888,342
Title:Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
Abstract:The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
Inventor(s): Kranzler; Jay D. (La Jolla, CA), Rao; Srinivas G. (Encinitas, CA)
Assignee: Cypress Bioscience, Inc. (San Diego, CA)
Application Number:12/644,510
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,888,342
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

United States Patent 7,888,342: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 7,888,342, hereafter referred to as the '342 patent, is a significant intellectual property asset that warrants a thorough analysis to understand its scope, claims, and the broader patent landscape it operates within. This analysis will delve into the patent's claims, its legal and technical context, and the implications for stakeholders.

Background of the Patent

The '342 patent is associated with pharmaceutical innovations, specifically relating to methods of treating certain medical conditions. To understand its significance, it is crucial to examine the background and the technological field it pertains to.

Claims of the '342 Patent

Claim Structure

The '342 patent includes a series of claims that define the scope of the invention. These claims are typically categorized into independent and dependent claims. Independent claims stand alone and define the invention broadly, while dependent claims build upon the independent claims and provide more specific details[4].

Key Claims

The asserted claims of the '342 patent, for instance, might involve a method for treating a specific condition by administering a particular drug or combination of drugs. For example, the claims might exclude the administration of certain amino acids like phenylalanine, tyrosine, or tryptophan, as seen in similar cases[5].

Scope of the Invention

Technical Scope

The technical scope of the '342 patent is defined by the claims and the detailed description provided in the patent specification. This includes the specific methods, materials, and processes involved in the invention. Understanding the technical scope is essential for determining what is protected and what is not.

Legal Scope

The legal scope involves the patent's enforceability and the rights granted to the patent holder. This includes the geographical jurisdiction, the term of the patent, and any limitations or exceptions that might apply.

Patent Landscape

Related Patents

The '342 patent is part of a larger patent landscape that includes other related patents and patent applications. This landscape can be mapped using tools like the USPTO's Patent Public Search or the Global Dossier, which provide access to related applications and their file histories[4].

Continuations and Family Members

Like the Cellect case, the '342 patent might have family members that include continuations, continuations-in-part, or divisional applications. These family members can have different patent terms and may be subject to different legal analyses, such as obviousness-type double patenting (ODP)[1].

Obviousness-Type Double Patenting (ODP)

ODP is a critical issue in patent law that prevents an inventor from securing a second, later-expiring patent for an invention covered by a patent that was filed at the same time but has a different patent term due to a grant of Patent Term Adjustment (PTA)[1].

Implications for the '342 Patent

If the '342 patent has family members with different expiration dates due to PTA, an ODP analysis would be necessary to ensure that the claims do not overlap in a way that extends the patent term beyond what is legally permissible.

Enforcement and Litigation

Case Law Precedents

The enforcement of the '342 patent can be influenced by case law precedents. For example, cases like Forest Labs. Holdings Ltd. v. Mylan Inc. provide insights into how similar patents have been litigated and the outcomes of such litigation[5].

Small Claims Patent Court Considerations

In the context of potential disputes, the concept of a small claims patent court, as studied by the Administrative Conference of the United States (ACUS), could provide a more streamlined and cost-effective avenue for resolving patent infringement claims involving the '342 patent[2].

Economic and Market Impact

Patent Claims Research Dataset

The USPTO's Patent Claims Research Dataset can provide valuable insights into the economic and market impact of the '342 patent. This dataset includes detailed information on claims from U.S. patents and can help in analyzing the scope and influence of the patent in the market[3].

Industry Expert Insights

Industry experts and legal practitioners, such as those involved in the ACUS study, can offer valuable perspectives on the economic and market implications of the '342 patent. Their insights can help in understanding how the patent fits into the broader industry landscape and its potential impact on competitors and consumers[2].

Key Takeaways

  • Claims and Scope: The '342 patent's claims define its technical and legal scope, which is crucial for understanding what is protected.
  • Patent Landscape: The patent is part of a larger landscape that includes related patents and applications, which can affect its enforceability and validity.
  • ODP Analysis: An ODP analysis is necessary to ensure that the patent does not extend beyond its legally permissible term.
  • Enforcement and Litigation: Case law and potential small claims patent courts can influence how the patent is enforced and litigated.
  • Economic Impact: The patent's economic and market impact can be analyzed using datasets and expert insights.

FAQs

What is the significance of the '342 patent in the pharmaceutical industry?

The '342 patent is significant because it protects a specific method of treating a medical condition, which can be a valuable asset for the patent holder in terms of market exclusivity and revenue.

How does ODP affect the '342 patent?

ODP prevents the '342 patent from having claims that are obvious variants of earlier-expiring patents, ensuring that the patent term is not extended beyond what is legally permissible.

What tools can be used to search for related patents to the '342 patent?

Tools such as the USPTO's Patent Public Search, Global Dossier, and the Common Citation Document (CCD) can be used to search for related patents and understand the broader patent landscape.

How might a small claims patent court impact disputes related to the '342 patent?

A small claims patent court could provide a more efficient and cost-effective way to resolve patent infringement disputes involving the '342 patent, making it more accessible for smaller entities to enforce their rights.

What kind of data can be used to analyze the economic impact of the '342 patent?

The USPTO's Patent Claims Research Dataset and other economic studies can provide valuable data to analyze the economic and market impact of the '342 patent.

Sources

  1. In re Cellect, LLC, United States Court of Appeals for the Federal Circuit, 2023.
  2. U.S. Patent Small Claims Court, Administrative Conference of the United States.
  3. Patent Claims Research Dataset, United States Patent and Trademark Office.
  4. Search for patents, United States Patent and Trademark Office.
  5. Forest Labs. Holdings Ltd. v. Mylan Inc., Robins Kaplan LLP Law Firm.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 7,888,342

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.